OraSure Reports 7% Revenue Drop in Q1 2026 Amid Core Business Decline
Event summary
- Q1 2026 revenue declined 7% YoY to $27.9M, with core business revenue down 0.5% YoY.
- Diagnostics revenue dropped 5% YoY due to lower HCV test sales.
- GAAP operating loss widened to $23.3M from $17.8M YoY.
- Company repurchased $5M worth of shares in Q1 2026.
- Guided Q2 2026 revenue to $27M–$30M.
The big picture
OraSure's Q1 2026 results reflect ongoing challenges in its core diagnostics business, particularly in HCV testing. The company is betting on regulatory milestones and strategic acquisitions to drive growth, while maintaining a focus on decentralizing diagnostics. The broader industry trend toward accessible, convenient, and affordable healthcare solutions underscores OraSure's strategic positioning, but its ability to execute on these initiatives will be critical.
What we're watching
- Regulatory Milestones
- The pace at which OraSure achieves its 2026 regulatory and commercial milestones will determine its growth trajectory.
- Acquisition Strategy
- Whether OraSure can leverage its strong balance sheet to pursue strategic acquisitions that strengthen its portfolio.
- Core Business Stability
- How OraSure will address the decline in its core diagnostics and sample management solutions revenues.
Related topics